Regorafenib combined with programmed cell death-1 inhibitor against refractory colorectal cancer and the platelet-to-lymphocyte ratio’s prediction on effectiveness

doi:10.4251/wjgo.v14.i4.920

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 4

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3439)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-3) series.

Item

Count

PDF

249

WORD

HTML

1907

Figures (1-4)

128

Tables (1-3)

145

Sum=2510

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

329

Download

600

Sum=929

Apr 15, 2022 (publication date) through Apr 19, 2024

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Oncol. Apr 15, 2022; 14(4): 920-934
Published online Apr 15, 2022. doi: 10.4251/wjgo.v14.i4.920

Full Size Figure Download Figure

Figure 1 Kaplan-Meier survival curves. A: Progression-free survival (PFS) of 30 patients; B: Overall survival of the whole cohort; C: PFS according to the patients with or without liver metastasis (P > 0.05); D: PFS according to previous exposure to regorafenib or not (P > 0.05). PFS: Progression-free survival; OS: Overall survival.

Citation: Xu YJ, Zhang P, Hu JL, Liang H, Zhu YY, Cui Y, Niu P, Xu M, Liu MY. Regorafenib combined with programmed cell death-1 inhibitor against refractory colorectal cancer and the platelet-to-lymphocyte ratio’s prediction on effectiveness. World J Gastrointest Oncol 2022; 14(4): 920-934
URL: https://www.wjgnet.com/1948-5204/full/v14/i4/920.htm
DOI: https://dx.doi.org/10.4251/wjgo.v14.i4.920